Vaccination

Vaccines
2
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 3 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
1
IMVAMUNE®Phase 41 trial
Active Trials
NCT03472014Completed22Est. Nov 2014
M&
Merck & Co.RAHWAY, NJ
3 programs
1
Girls OnGuardPhase 31 trial
Informational Animation VideoN/A1 trial
Rotavirus VaccineN/AVaccine1 trial
Active Trials
NCT06890403Recruiting6,000Est. Jan 2027
NCT05212935Unknown2,000Est. Apr 2023
NCT00813319Completed216Est. Mar 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Bavarian NordicIMVAMUNE®
Merck & Co.Girls OnGuard
Merck & Co.Informational Animation Video
Merck & Co.Rotavirus Vaccine

Clinical Trials (4)

Total enrollment: 8,238 patients across 4 trials

Special Access Program IMVAMUNE®

Start: Apr 2010Est. completion: Nov 201422 patients
Phase 4Completed

Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females

Start: Oct 2009Est. completion: Mar 2014216 patients
Phase 3Completed
NCT06890403Merck & Co.Informational Animation Video

Can Stories Encourage the Elderly to Vaccinate? Combining Viewer-tailored Personal Narrative Videos With Informational Videos to Improve Vaccine Uptake Among Older Adults

Start: Sep 2025Est. completion: Jan 20276,000 patients
N/ARecruiting
NCT05212935Merck & Co.Rotavirus Vaccine

A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy

Start: May 2022Est. completion: Apr 20232,000 patients
N/AUnknown

Related Jobs in Vaccines

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 8,238 patients
2 companies competing in this space